» Articles » PMID: 38355910

A Comparison of Long-term Outcomes by Donor Type in the Era of Post-transplantation Cyclophosphamide for Aggressive Adult T-cell Leukemia/lymphoma

References
1.
Bazarbachi A, Reef D, Narvel H, Patel R, Al Hamed R, Vikash S . Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma. Clin Hematol Int. 2023; 5(2-3):78-91. PMC: 10241770. DOI: 10.1007/s44228-023-00032-y. View

2.
Utsunomiya A . Progress in Allogeneic Hematopoietic Cell Transplantation in Adult T-Cell Leukemia-Lymphoma. Front Microbiol. 2019; 10:2235. PMC: 6797831. DOI: 10.3389/fmicb.2019.02235. View

3.
Nosaka K, Iwanaga M, Imaizumi Y, Ishitsuka K, Ishizawa K, Ishida Y . Epidemiological and clinical features of adult T-cell leukemia-lymphoma in Japan, 2010-2011: A nationwide survey. Cancer Sci. 2017; 108(12):2478-2486. PMC: 5715256. DOI: 10.1111/cas.13398. View

4.
Tanaka T, Nakamae H, Ito A, Fuji S, Hirose A, Eto T . A Phase I/II Multicenter Trial of HLA-Haploidentical PBSCT with PTCy for Aggressive Adult T Cell Leukemia/Lymphoma. Transplant Cell Ther. 2021; 27(11):928.e1-928.e7. DOI: 10.1016/j.jtct.2021.07.010. View

5.
Ito A, Nakano N, Tanaka T, Fuji S, Makiyama J, Inoue Y . Improved survival of patients with aggressive ATL by increased use of allo-HCT: a prospective observational study. Blood Adv. 2021; 5(20):4156-4166. PMC: 8945611. DOI: 10.1182/bloodadvances.2021004932. View